Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Werewolf Therapeutics (HOWL – Research Report) yesterday and set a price target of $9.00. The company’s shares closed ...

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other ...

It was a presentation at the American Society of Hematology (ASH) conference that swayed Jazz Pharmaceuticals to put up $15 million upfront to join Werewolf Therapeutics on the prowl. The backloaded ...

Werewolf Therapeutics, Inc. (HOWL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...

Werewolf Therapeutics, Inc. (HOWL) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, HOWL's 50-day simple moving average ...

Director Luke Evnin reported selling shares of Werewolf Therapeutics Inc (NASDAQ:HOWL) between December 2nd and December 4th, 2025. The sales, executed under a prearranged 10b5-1 trading plan, totaled ...

MPM Asset Management LLC and related entities, all of whom are 10% owners of Werewolf Therapeutics, Inc. (NASDAQ:HOWL), sold a total of 179551 shares of common stock for approximately $179,551. The ...

Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

A few weeks back you might recall that we gave you the first heads up on a new werewolf film on the horizon called Howl (“Fever Pitch Ready to Howl” – November 2007). Since that story went up, ...